Clinical Trial Update: Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating gefitinib combined with anlotinib in advanced non-squamous non-small cell lung cancer with uncleared plasma ctDNA EGFR mutatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Second Affiliated Hospital of Nanchang University | Conditions: Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Status: UNKNOWN